IP Verse

Sustained-Release Dosage Forms Of Ruxolitinib

Patent No. EP2919766 (titled "Sustained-Release Dosage Forms Of Ruxolitinib") was filed by Incyte on Nov 14, 2013. The application was issued on May 26, 2021.

Patent Summary

Sustained-release oral dosage form of ruxolitinib, a JAK inhibitor, that reduces the frequency of dosing while maintaining therapeutic efficacy. The dosage form contains ruxolitinib and a sustained-release matrix former like hydroxypropyl methylcellulose. Administering this formulation to humans results in lower peak and trough plasma concentrations of ruxolitinib compared to immediate-release tablets. It also reduces the number of daily doses needed to treat JAK-associated diseases like autoimmunity and myeloproliferative disorders. The sustained-release formulation provides a more consistent and predictable ruxolitinib plasma profile.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ALFRED E TIEFENBACHERFeb 28, 2022HAMM & WITTKOPP
STADA ARZNEIMITTELFeb 28, 2022HAMM & WITTKOPP
MAIWALDFeb 25, 2022MAIWALD
TEVA PHARMACEUTICALSFeb 25, 2022D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2919766

INCYTE
Application Number
EP13798840A
Filing Date
Nov 14, 2013
Status
Granted And Under Opposition
Apr 23, 2021
Publication Date
May 26, 2021
External Links
Slate, Register , Google Patents